Accessibility Menu
Integral Diagnostics logo

Integral Diagnostics(ASX) IDX

Market CapA$838.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)+68%
5 Year-52%
1 Year-13%
1 Month+9%
A$2.25
-1.32%
-0.03Today
Integral Diagnostics last closing stock price
MetricPriceDate
Last closeAUD 2.252026-08-21
Integral Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.45%AUD 2.242026-08-14
1 month+9.22%AUD 2.062026-07-22
3 month+8.17%AUD 2.082026-05-22
Year to date-10.2%AUD 2.512025-12-31
1 year-12.74%AUD 2.582025-08-21
3 year-23.1%AUD 2.932023-08-22
5 year-51.59%AUD 4.652021-08-20
Since inception+67.92%AUD 1.342015-10-21

Integral Diagnostics Financials at a Glance

Market Cap

A$838.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$1.26B

Net Income (TTM)

A$19.69M

EPS (TTM)

A$0.04

P/E Ratio

59.68

Dividend

A$0.07

Beta (Volatility)

0.12 (Low)

Price

A$2.25

Volume

862,260

Open

A$2.28

Previous Close

A$2.25

Daily Range

A$2.21 - A$2.28

52-Week Range

A$1.91 - A$3.07

Estimated Earnings Date

Aug 25, 2026

IDX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Integral Diagnostics

Integral Diagnostics Limited operates within the healthcare sector, providing essential diagnostic imaging services across Australia and New Zealand. The company manages a network of 67 radiology clinics, delivering services to general practitioners, medical specialists, and allied health professionals.

Products and Services
  • Diagnostic imaging services including X-rays, MRIs, and CT scans
  • Specialized imaging services for various medical conditions
  • Telehealth services to enhance patient access to diagnostics
Growth Outlook
  • Revenue increased to AUD 393.5 million in the latest quarter
  • Operating income improved to AUD 33.3 million, reflecting operational efficiency
  • Expansion plans include new clinic openings and service enhancements
Financial Highlights
  • Net income of AUD 8.96 million reported for the latest quarter
  • Trailing twelve months (TTM) revenue of AUD 1.5 billion, showing consistent growth
  • Dividend yield of 3.30%, indicating a commitment to returning value to shareholders
Integral Diagnostics Limited has established itself as a key player in the medical diagnostics industry, focusing on high-quality imaging services. The company’s recent financial performance demonstrates a positive trajectory, with significant revenue growth and improved operating income. The expansion strategy aims to enhance service delivery and patient access, positioning the company for continued success in the healthcare sector. With a solid dividend yield, Integral Diagnostics presents an attractive opportunity for investors interested in the healthcare industry.
AI Generated • Aug 20, 2026

Industry

Healthcare Providers and Services

Employees

2,779

CEO

Ian Kadish, MBA, PhD

Headquarters

Melbourne, VIC 3000, AU

IDX Financials

Key Financial Metrics (TTM)

Gross Margin

22.17%

Operating Margin

9.18%

Net Income Margin

1.83%

Return on Equity

2.05%

Return on Capital

4.50%

Return on Assets

0.99%

Earnings Yield

1.68%

Dividend Yield

3.24%

Payout Ratio

1.55%

Stock Overview

Market Cap

A$838.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

372.49M

Volume

862.26K

Avg. Volume

1.22M

Financials (TTM)

Gross Profit

A$300.99M

Operating Income

A$148.05M

EBITDA

A$210.63M

Operating Cash Flow

A$157.57M

Capital Expenditure

-A$96.74M

Free Cash Flow

A$60.83M

Cash & ST Invst.

A$34.12M

Total Debt

A$841.54M

Integral Diagnostics Performance Analysis

Integral Diagnostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 358,739,000N/A
20232023-06-30AUD 440,099,00022.7%
20242024-06-30AUD 469,697,0006.7%
20252025-06-30AUD 627,215,00033.5%
Integral Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-303.1%
Q22024-12-316.1%
Q42025-06-3048.0%
Q22025-12-315.1%
Integral Diagnostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD 0.07N/A
20232023-06-30AUD 0.1156.2%
20242024-06-30AUD -0.26N/A
20252025-06-30AUD 0.02N/A
Integral Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30108.9%
Q22024-12-31-106.2%
Q42025-06-30950.0%
Q22025-12-3175.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$393.48M

+70.2%

Gross Profit

A$84.82M

+65.8%

Gross Margin

21.56%

N/A

Market Cap

A$838.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$279.37K

N/A

Employees

3,000

N/A

Net Income

A$8.96M

+113.4%

EBITDA

A$70.21M

+323.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$34.12M

+89.7%

Total Debt

A$841.54M

+132.8%

Accounts Receivable

A$27.76M

-22.0%

Inventory

A$2.95M

+59.1%

Long Term Debt

A$821.83M

+139.2%

Short Term Debt

A$19.71M

-44.9%

Return on Assets

0.99%

N/A

Return on Invested Capital

5.46%

N/A

Free Cash Flow

A$7.98M

+131.9%

Operating Cash Flow

A$32.85M

+115.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PNV.AXPolyNovo Limited
A$1.07-3.60%
NAN.AXNanosonics Limited
A$3.63+0.83%
ACL.AXAustralian Clinical Labs Limited
A$2.96+2.42%
OCA.AXOceania Healthcare Limited
A$0.68+0.75%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About IDX

What is the current price of Integral Diagnostics?

Integral Diagnostics is trading at A$2.25 per share.

What is the 52-week range for Integral Diagnostics?

Over the past 52 weeks, Integral Diagnostics has traded between A$1.91 and A$3.07.

How much debt does Integral Diagnostics have?

As of the most recent reporting period, Integral Diagnostics reported total debt of A$585.01M.

How much cash does Integral Diagnostics have on hand?

Integral Diagnostics reported A$52.10M in cash and cash equivalents in its most recent financial results.

What is Integral Diagnostics’s dividend yield?

Integral Diagnostics currently has a dividend yield of 3.24%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.